Recently, PGV-1 showed a strong inhibitory effect against 4T1 cells, a triple-negative breast cancer (TNBC) cell model, under in vitro experiment through ROS generation.12 These studies warrant the potency of PGV-0 and PGV-1 to be further investigated as anticancer drugs, especially to the specific types of breast cancers, namely HER2 positive and TNBC. Here, ERBB2 is linked to breast carcinoma.